Exenatide

Key Benefits#

• Blood glucose control in type 2 diabetes
• Weight loss (average 2–3 kg in clinical trials)
• Once-weekly extended-release formulation available
• Reduces appetite and food intake
• Possible neuroprotective in Parkinson's disease (Phase II trials)
• Reduces systemic inflammation
• May protect pancreatic beta cells
• Cardiovascular neutral or potentially protective

Mechanism of Action#

Exenatide activates GLP-1 receptors identically to human GLP-1 but with 4-5x higher potency and prolonged action. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic GLP-1R. Unlike mammalian GLP-1, exenatide is not degraded by DPP-4 (dipeptidyl peptidase-4) due to its different N-terminal sequence. Exenatide also crosses the blood-brain barrier and activates GLP-1Rs on dopaminergic neurons in the substantia nigra, where it reduces oxidative stress and neuroinflammation — the basis for its Parkinson's research.

Dosing Protocols#

Side Effects#

• Nausea (most common, especially initially)
• Vomiting
• Diarrhea
• Headache
• Injection site nodule (Bydureon — microspheres)
• Hypoglycemia (with insulin/sulfonylureas)
• Rare: pancreatitis
• Rare: renal impairment worsening at high doses

Contraindications#

End-stage renal disease (GFR < 30 mL/min): avoid Byetta. History of pancreatitis. Not for T1DM. Use with caution in severe GI disease. Pregnancy: insufficient data.

Storage#

Byetta pens: 2–8°C (unused), room temperature up to 77°F for 30 days in use. Bydureon: 2–8°C, can be at room temp up to 4 weeks. Never freeze.

Featured In Stacks#

1. 1.
   Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model

   Li S, Chen Q, Liu H, Chen Z, Ding N, Sun T et al. · Neuroscience · 2026PubMed Verified

2. 2.
   Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

   Behers BJ, Sanchez C, Hozayen O, Hozayen Y, Kammer R, Corrigan WT et al. · Journal of cardiovascular development and disease · 2026ReviewPubMed Verified

3. 3.
   A study to evaluate the impact of PB-119 injection (a pegylated exenatide formulation) on the pharmacokinetic profiles of Digoxin and Warfarin sodium in healthy subjects

   Yu Y, Hu W, Zhang T, Peng Y, Ding J, Wang X et al. · SAGE open medicine · 2026PubMed Verified

4. 4.
   Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials

   Chiappa GR, Santos PCN, Cavalcante DVS, Sá Filho AS, Prado N, Lombardo KM et al. · Diabetes, obesity & metabolism · 2026ReviewPubMed Verified

5. 5.
   Exenatide through PPARδ improved hepatic insulin resistance in patients of type 2 diabetes mellitus via suppressing pyroptosis

   Li X, Zhou T, Wu Y, Sun J, Wang Z, Huang Y et al. · International immunopharmacology · 2026PubMed Verified

6. 6.
   The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis

   Hertzer LA, Siegel RM, Kharofa RY, Stackpole KM, Mahabee-Gittens EM · Childhood obesity (Print) · 2026Meta-AnalysisPubMed Verified

7. 7.
   Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis

   Belančić A, Antza C, Poutachidis A, Palaska S, Gkrinia EMM, Faour AK et al. · British journal of clinical pharmacology · 2026PubMed Verified

8. 8.
   Peptide Mapping Using Multienzyme Digestion Strategies Integrated with LC-HRMS Workflow: A Case Study

   Maheshwari D, Badgujar D, Kumar G, Sharma N · Journal of peptide science : an official publication of the European Peptide Society · 2026PubMed Verified

9. 9.
   Emerging and Established Pharmacotherapies for Smoking Cessation: A Review

   Huhulea EN, Frishman WH, Aronow WS · Cardiology in review · 2026PubMed Verified

10. 10.
    Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov

    Patil S, Jha N, Jha MK · Addictive behaviors reports · 2026PubMed Verified

11. 11.
    Systemic Pharmacokinetic Principles of Therapeutic Peptides

    Nordell P, Jansson-Löfmark R, Gennemark P · Clinical pharmacokinetics · 2026PubMed Verified

12. 12.
    Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice

    Huang Y, Lin X, Deng M, Tang Y, Li S, Xu B et al. · EBioMedicine · 2026PubMed Verified

13. 13.
    Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials

    Stefanou MI, Panagiotopoulos E, Tentolouris A, Theodorou A, Papagiannopoulou G, Athanasaki A et al. · Therapeutic advances in neurological disorders · 2026PubMed Verified

14. 14.
    Glucagon-Like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Srisurapanont M, Suttajit S, Likhitsathian S, Suradom C, Maneeton B · International journal of psychiatry in medicine · 2026PubMed Verified

15. 15.
    Exenatide induces an Enhanced Endogenous Glucagon-like Peptide-1 Secretory Response in Patients receiving Basal Insulin

    Parikh M, MMath JP, Shen J, Kramer CK, Zinman B, Beaudry JL et al. · The Journal of clinical endocrinology and metabolism · 2026PubMed Verified

16. 16.
    Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes

    Santos P, Sá Filho AS, Aprigliano V, Duarte AG, Ribeiro NA, Lombardo KM et al. · Pharmaceutics · 2026ReviewPubMed Verified

17. 17.
    GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study

    Salmanoglu M, Ercan G, Genç HS, Gül SS, Aygün H · Medicina (Kaunas, Lithuania) · 2026PubMed Verified

18. 18.
    A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms

    Voros C, Chatzinikolaou F, Papapanagiotou I, Polykalas S, Mavrogianni D, Koulakmanidis AM et al. · International journal of molecular sciences · 2026Meta-AnalysisPubMed Verified

19. 19.
    Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis

    Ailawadi S, Murphy JE, Storandt MH, Mahipal A · Cancers · 2026PubMed Verified

20. 20.
    Engineering Marker-Free Lettuce Chloroplast Genome to Express Functional Glucagon-Like Peptide-1 Receptor Agonists Exenatide and Lixisenatide

    Singh R, Daniell H · Plant biotechnology journal · 2026PubMed Verified

21. 21.
    The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease

    Teil M, Huot P · Current opinion in neurobiology · 2026ReviewPubMed Verified

22. 22.
    Glucagon-like Peptide-1 Receptor Agonists as a Dual-target Strategy for Depression and Metabolic Health: A Narrative Review

    Kumar V, Sudha TYS, Bhattacharjee D, Mateen A, Mahato SK · Annals of African medicine · 2026PubMed Verified

23. 23.
    Systematic Review of Therapeutic Strategies for Reducing Parkinson's Disease Symptoms and Progression

    Tumu S, Maram Reddy VY, Jayasuriya N, Ali M, Munir A, Malasevskaia I et al. · Cureus · 2025ReviewPubMed Verified

24. 24.
    The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials

    O'Mara A, Mody BP, Mammi M, Simjian T, Ghattas K, Kaliki S et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Meta-AnalysisPubMed Verified

25. 25.
    Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management

    Riccioni G, Notarangelo C, Riccioni M, D'Orazio N · International journal of molecular sciences · 2025ReviewPubMed Verified

26. 26.
    GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies

    Giugliano D, Longo M, Di Martino N, Scappaticcio L, Caruso P, Bellastella G et al. · Diabetes, obesity & metabolism · 2026PubMed Verified

27. 27.
    GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models

    Baumer-Harrison C, Aldaghma D, White AD, Applebey SV, Pataro AM, Mohiby AZ et al. · Diabetes, obesity & metabolism · 2026PubMed Verified

28. 28.
    Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review

    Deameh MG, Ramez M, Rowaiee R, Bani Irshid BA, Mohamed H, Abdelshafi A et al. · The journal of sexual medicine · 2026Meta-AnalysisPubMed Verified

29. 29.
    Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024

    Fat MN, Johnson HC, Farberg AS · Journal of drugs in dermatology : JDD · 2026PubMed Verified

30. 30.
    GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization

    Mahadevan A, Vosooghi A, Arora JS, Kumar RS, Singh G, Tsai KK et al. · The Journal of clinical endocrinology and metabolism · 2026PubMed Verified

31. 31.
    JNK3 regulates β cell responses to incretins in human islets and mouse models

    Louzada RA, Gonzalez Medina M, Pita-Grisanti V, Bouviere J, Neves AF, Almaça J et al. · The Journal of clinical investigation · 2026PubMed Verified

32. 32.
    The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials

    Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T et al. · Life (Basel, Switzerland) · 2025ReviewPubMed Verified

33. 33.
    Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis

    Tsironikos GI, Tsolaki V, Zakynthinos GE, Kyprianidou D, Rammou V, Antonogiannis T et al. · Frontiers in clinical diabetes and healthcare · 2025Meta-AnalysisPubMed Verified

34. 34.
    Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols

    Davila Diaz R, Campos Barrera E, Diaz Fosado LA, Reyes Esparza A, Perez Benitez OA · Cureus · 2025ReviewPubMed Verified

35. 35.
    GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach

    Santiago JA, Gutierrez-Silva JC, Hsu WC, Sanchez K, Almanza C, Ramos W et al. · Trends in molecular medicine · 2025ReviewPubMed Verified

36. 36.
    Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis

    Tsironikos GI, Tsolaki V, Zakynthinos G, Rammou V, Kyprianidou D, Antonogiannis T et al. · Diabetes/metabolism research and reviews · 2026Meta-AnalysisPubMed Verified

37. 37.
    Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence

    Taj S, Zuber M, Rashid M, Chhabra M, Undela K, Rawal S et al. · Diabetes, obesity & metabolism · 2026Meta-AnalysisPubMed Verified

38. 38.
    Spatially diffuse cAMP signalling with oppositely biased GLP-1 receptor agonists in β-cells despite differences in receptor localisation

    Chen S, Lobato CB, Wong C, Manchanda Y, Viloria K, Davies I et al. · Molecular metabolism · 2026PubMed Verified

39. 39.
    RYGB induces vagal sensory neuropathy characterized by altered Glp1r expression and enhanced exendin-4 responsiveness in male mice

    Merchant W, Tinajero A, Khan A, Chu Y, Saleh S, Tasabehji D et al. · American journal of physiology. Endocrinology and metabolism · 2026PubMed Verified

40. 40.
    Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation

    Alansari AO, Alharbi AS, Alshehri KM, Alhabib AT, Alsalmi BS, Almosfer WA et al. · Medicine · 2025Meta-AnalysisPubMed Verified

41. 41.
    Formulation and characterization of exenatide-loaded PLGA microspheres prepared by coacervation

    White C, Schwendeman SP · Drug delivery and translational research · 2025PubMed Verified

42. 42.
    GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions

    Gandhi A, Parhizgar A · Frontiers in endocrinology · 2025ReviewPubMed Verified

43. 43.
    Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4

    Jung JE, Park SB, Yu HY, Yoon SB, Kim J · European journal of pharmacology · 2026PubMed Verified

44. 44.
    GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study

    Gonzalez F, Reid MW, Garcia JF, Raymond JK, Chao LC · Journal of pediatric endocrinology & metabolism : JPEM · 2026PubMed Verified

45. 45.
    Design of biomimetic chylomicrons based on 1,3-diolein grafted hyaluronic acid to drive biomacromolecules across the intestinal mucosal barrier

    Cui S, An Y, Cui Z, Liu S, Li H, Wen X et al. · Journal of controlled release : official journal of the Controlled Release Society · 2026PubMed Verified

46. 46.
    Glucagon-like peptide-1 receptor (GLP-1R) agonists prevent tributyltin-induced muscle atrophy/wasting via restoring GLP-1R signaling in vitro and in mice

    Yang RS, Lin YC, Lan KC, Wang CC, Tzeng HP, Chang TY et al. · Ecotoxicology and environmental safety · 2026PubMed Verified

47. 47.
    Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling

    Gao Y, Zhong Y, Guan R, Yu Q, Liu H, Tuersun A et al. · Drug metabolism and disposition: the biological fate of chemicals · 2025PubMed Verified

48. 48.
    The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis

    Sinha B, Ghosal S · Addiction science & clinical practice · 2025Meta-AnalysisPubMed Verified

49. 49.
    Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis

    Eshraghi R, Ghadimi DJ, Montazerinamin S, Bahrami A, Kachela Y, Rezasoltani M et al. · EClinicalMedicine · 2025PubMed Verified

50. 50.
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review

    Zacharia GS, Gongati SR, Kharel A, Jacob A · Cureus · 2025ReviewPubMed Verified